[Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome]

Ann Biol Clin (Paris). 2018 Apr 1;76(2):217-223. doi: 10.1684/abc.2018.1324.
[Article in French]

Abstract

Congenital disorders of glycosylation (CDG) are rare inborn diseases of glycan component of N-glycosylated proteins. We report here the case of a 28-year-old patient with CDG syndrome type Ia, who presented with a deep venous thrombosis in the left suro-popliteal vein with no known triggers or antecedents. The patient was treated with rivaroxaban for six months. Blood tests performed after discontinuing anticoagulant treatment showed multiple abnormalities affecting the proteins involved in haemostasis (both coagulation factors and inhibitors), i.e. a combined factor XI, antithrombin and protein C deficiency (35%, 41%, and 42% respectively) associated with a moderate increase of FVIII (179%) and VWFAg (163%) without inflammation. Patient results are here discussed with regard to the limited number of articles addressing haemostasis in this rare disease, as the occurrence of deep venous thrombosis remains uncommon in the literature.

Keywords: CDG syndrome; antithrombin deficiency; deep venous thrombosis; factor XI deficiency; protein C deficiency.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Congenital Disorders of Glycosylation / complications
  • Congenital Disorders of Glycosylation / drug therapy*
  • Female
  • Humans
  • Phosphotransferases (Phosphomutases) / deficiency*
  • Rare Diseases
  • Rivaroxaban / therapeutic use*
  • Treatment Outcome
  • Venous Thrombosis / complications
  • Venous Thrombosis / drug therapy*

Substances

  • Rivaroxaban
  • Phosphotransferases (Phosphomutases)

Supplementary concepts

  • Congenital disorder of glycosylation type 1A